Trial Profile
A Phase 2 Study of ABT-199 in Combination With Ibrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (AIM Study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms AIM
- 17 Aug 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2025.
- 01 May 2022 Planned End Date changed from 1 Jun 2018 to 1 Jun 2023.
- 01 May 2022 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2023.